Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026

Core Viewpoint - Vericel Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, showcasing its advancements in therapies for sports medicine and severe burn care [1]. Company Overview - Vericel Corporation is a leader in advanced therapies for sports medicine and severe burn care, combining biological innovations with medical technologies to create a differentiated portfolio of cell therapies and specialty biologics [2]. - The company markets three primary products in the United States: - MACI® is an autologous cellularized scaffold product for repairing full-thickness cartilage defects in the knee [2]. - Epicel® is a permanent skin replacement for treating deep dermal or full-thickness burns covering 30% or more of total body surface area [2]. - Vericel holds an exclusive license for NexoBrid®, a biological orphan product for eschar removal in burn patients [2].